Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study
Open Access
- 1 December 2022
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (12) , 5847-5858
Abstract
Background/Aim: Bevacizumab and chemotherapy are used in glioblastoma multiforme (GBM) relapse. However, the choice of chemotherapeutic agent remains an open question and this study aimed to evaluate the efficacy and safety of different combinations. Patients and Methods: Between June 2005 and August 2020, all patients treated with chemotherapy plus bevacizumab (BVZ) for recurrent glioblastoma in the Georges-François Leclerc Cancer Center, Dijon, France were included in this retrospective comparative study. The primary objective was progression-free survival (PFS) and as secondary objectives, overall survival (OS), disease control rate (DCR), and safety were investigated. Factors associated with response were also analyzed. Results: A total of 160 patients were screened: 100 received fotemustine plus BVZ (62%) and 62 (38%) received another cytotoxic agent plus BVZ: 35 (22%) irinotecan (IRI), 18 (11%) temozolomide (TEM), and 7 (4%) lomustine (LOM). In the whole population, median PFS was 4.47 months, median OS was 9 months, and 3-month DCR was 51%. Regarding survival according to treatment, median OS was significantly lower in the fotemustine group compared to that in other cytotoxic agents: 7.3 vs. 19.9 months. In the fotemustine group, steroids use at baseline and low Karnofsky performance status were associated with poor median OS. Grade 3-4 adverse events were found in 21.9%, with no difference between groups, but 7 patients had grade 5 adverse events in the fotemustine group. Conclusion: Using real-life data, this study showed lower efficacy of fotemustine and bevacizumab, as compared to IRI or TEM or LOM-BVZ combinations.Keywords
This publication has 35 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustineJournal of Neuro-Oncology, 2015
- Antiangiogenic therapy for high-grade gliomaCochrane Database of Systematic Reviews, 2014
- Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)Journal of Neuro-Oncology, 2013
- Bevacizumab and daily temozolomide for recurrent glioblastomaCancer, 2011
- Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyJournal of Neuro-Oncology, 2010
- A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastomaJournal of Neuro-Oncology, 2010
- Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II studyJournal of Neuro-Oncology, 2010
- Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumorsCancer, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007